Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~6 days
Time for 50 % to be eliminated
Steady State
~25.9 days
≈ 4.3 half-lives
Accumulation
×1.80
Cmax at steady state ÷ Cmax first dose
Gone After
~42 days
after last dose
Source: Jastreboff et al., NEJM 2023 (TRIUMPH program, Eli Lilly). Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Retatrutide: ~6 days.
Retatrutide has a reported half-life of about 6 days. Under a weekly dosing schedule, steady state is reached at roughly 4.3 half-lives — about 26 days — and subsequent doses accumulate by a factor of about 1.8 over a single dose.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 42 days — seven half-lives.
Retatrutide is a triple GLP-1/GIP/GCG receptor agonist studied at weekly doses of 0.5 to 12 mg. The long half-life is what makes weekly dosing feasible and steady-state accumulation predictable.